CompletedNCT03325556
Pimavanserin or Placebo to Prevent Relapse in Dementia-Related Psychosis
About this title
Read the official source — NCT03325556Medication studyAges 50–90Multiple countriesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 50 years to 90 years.
- Listed locations
- Costa Mesa and 82 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 27, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 392
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, United Kingdom, ...
- Age range
- From 50 Years to 90 Years
- Official registry ID
- NCT03325556
- Official title
Show the full official title
A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Costa Mesa, United States · Fullerton, United States · Aventura, United States
67 more locations
- Boca Raton, United States
- Miami, United States
- Naples, United States
- Orlando, United States
- Ormond Beach, United States
- Pompano Beach, United States
- Winfield, United States
- Kansas City, United States
- Quincy, United States
- Chesterfield, United States
- St Louis, United States
- Las Vegas, United States
- Eatontown, United States
- Toms River, United States
- Albany, United States
- New York, United States
- Staten Island, United States
- North Canton, United States
- Philadelphia, United States
- Willow Grove, United States
- Knoxville, United States
- Charlottesville, United States
- Rousse, Bulgaria
- Antofagasta, Chile
- Santiago, Chile
- Hradec Králové, Czechia
- Prague, Czechia
- Rychnov nad Kněžnou, Czechia
- Marseille, France
- Toulouse, France
- Tübingen, Germany
- Padova, Italy
- Rome, Italy
- Torino, Italy
- Bydgoszcz, Poland
- Gdansk, Poland
- Katowice, Poland
- Lublin, Poland
- Poznan, Poland
- Siemianowice Śląskie, Poland
- Szczecin, Poland
- Warsaw, Poland
- Belgrade, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Banská Bystrica, Slovakia
- Košice, Slovakia
- Krompachy, Slovakia
- Svidník, Slovakia
- Vranov nad Topľou, Slovakia
- Barcelona, Spain
- Sant Cugat del Vallès, Spain
- Seville, Spain
- Oleksandrivka, Ukraine
- Dnipro, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Vinnytsia, Ukraine
- Zaporizhzhya, Ukraine
- Bath, United Kingdom
- Blackpool, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
- Czechia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including Placebo, Pimavanserin 34 mg and Pimavanserin 20 mg.
Who was this study for?
Listed age limits: 50 years to 90 years.
